Full Breakdown
Johnson & Johnson Launches Four Drugs on TrumpRx Platform
4/25/2026, 8:54:54 AM
Deal Overview: Johnson & Johnson Joins TrumpRx
Johnson & Johnson will begin marketing four prescription drugs on the Trump administration’s TrumpRx website on Friday. The move follows a voluntary January agreement that links the listing of the drugs to an exemption from the administration’s tariff policy, with the stated aim of lowering costs for Americans by expanding Medicaid access to affordable prescriptions.
Background: TrumpRx Initiative and Prior Partnerships
TrumpRx, launched in February, is a government-backed site that offers discounted prices to cash-pay patients who lack insurance coverage for a prescription. Since its launch, the platform has added products from Pfizer, Novo Nordisk, Eli Lilly and AstraZeneca under “most-favoured-nation” pricing deals intended to reduce U.S. drug costs and spur domestic production. Johnson & Johnson’s entry more than doubles the number of drugs available. The initiative aligns with the administration’s broader effort to curb prescription drug spending.
Medications Added to the Platform
CBS News lists the four drugs as metformin, metformin extended-release, Invokana and Xarelto. Reuters reports the drugs as Invokamet, Invokamet XR, Invokana and Xarelto, noting that Invokamet products combine metformin with sitagliptin. All four will be sold through TrumpRx and Johnson & Johnson’s direct-to-consumer site, JNJ Direct.
Investment and Platform Growth
Johnson & Johnson previously pledged a $55 billion investment in research and production facilities, including sites in Pennsylvania and North Carolina. The addition of its drugs more than doubles TrumpRx’s catalog, reflecting rapid growth since the site’s launch.
Official Statements & Responses
Johnson & Johnson told Reuters it would begin offering the four medications on TrumpRx and on JNJ Direct. Reuters noted the company did not immediately respond to a request for comment. No separate statement from the Trump administration appears in the sources.
Criticism & Opposition
The discounted rates on TrumpRx apply only to uninsured patients or those whose insurance does not cover the listed drugs, requiring full out-of-pocket payment. Insured patients typically receive lower prices through existing coverage, limiting the platform’s benefit for a broader population. Analysts also note that the model’s durability is uncertain, questioning whether tying tariff exemptions to drug pricing can provide lasting affordability.
Conflicting Reports & Gaps
Sources differ on the drug names. CBS News lists metformin and metformin extended-release, while Reuters identifies Invokamet and Invokamet XR, which are metformin-based combination products. Reuters also reported it could not verify which four drugs were slated for the site. Johnson & Johnson did not comment to clarify the discrepancy.
What's Next
The four medications will become available on TrumpRx and JNJ Direct starting Friday. Other manufacturers, including Pfizer, Novo Nordisk, Eli Lilly and AstraZeneca, have entered similar agreements.
